MLKL and non-small cell lung carcinoma: Further, transient knockdown of MLKL by siRNA compromised cisplatin-reduced cell viability in both H1299R-shSkp2 and A549R-shSkp2 stable cells, confirming the critical role of MLKL in cisplatin resistance in NSCLC (Fig. 7d, e).